Currently, there are 83.71M common shares owned by the public and among those 82.95M shares have been available to trade.
The company’s stock has a 5-day price change of 1.90% and 62.74% over the past three months. EDIT shares are trading 68.50% year to date (YTD), with the 12-month market performance down to -61.02% lower. It has a 12-month low price of $0.91 and touched a high of $6.05 over the same period. EDIT has an average intraday trading volume of 1.99 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.64%, 34.99%, and 3.00% respectively.
Institutional ownership of Editas Medicine Inc (NASDAQ: EDIT) shares accounts for 54.29% of the company’s 83.71M shares outstanding.
It has a market capitalization of $179.15M and a beta (3y monthly) value of 2.11. The earnings-per-share (ttm) stands at -$3.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.80% over the week and 6.48% over the month.
Earnings per share for the fiscal year are expected to increase by 34.40%, and 42.87% over the next financial year. EPS should grow at an annualized rate of 27.74% over the next five years, compared to -1.48% over the past 5-year period.
Looking at the support for the EDIT, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on April 28, 2025, with the firm’s price target at $3. Truist was of a view on December 13, 2024 that the stock is Hold, while Stifel gave the stock Hold rating on December 13, 2024, issuing a price target of $11- $3. Chardan Capital Markets on their part issued Neutral rating on December 13, 2024.
